Opto Circuits (India) Ltd.
Snapshot View

4.42 +0.01 ▲0.2%

23 July 2021, 04:00:00 P.M.
Volume: 83,566

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Medical Equipment/Supplies/Accessories Compare with Industry peers
Website http://www.optoindia.com
Financial Indicators
Market Cap 132.28 Cr.
Earnings per share (EPS) -4.27 Trailing Twelve Months Ending 2020-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2020-12
Industry PE - Trailing Twelve Months Ending 2020-12
Book Value / Share -7.65 Trailing Twelve Months Ending 2020-12
Price to Book Value -0.58 Calculated using Price: 4.40
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 30.06 Cr. 300,625,744 Shares
FaceValue 10
Company Profile

Opto Circuits India (OCI), incorporated in the year 1992 is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries. The manufacturing is backed by a complete range of inspection and reliability testing equipments such as Bond Pull, Shear Testers, Stereo Microscopes, IR Viewers Spectrometers and many more.

OCI specialize in cardiac and vital signs monitoring, emergency cardiac care, vascular treatments and sensing technologies. Its products are US FDA listed and CE marked. Some of the well-known brands marketed by the company are Criticare Systems, Mediaid, Unetixs Vascular, Eurocor and Cardiac Science.

The company has customers in USA, Europe, Middle East, Far East, South Africa etc. To service these customers it has offices through its subsidiaries in USA, Germany, Singapore and Dubai. It has subsidiaries namely Mediaid Inc (USA), Eurocor Gmbh (Germany), Criticare Systems Inc (USA), Advanced Micronic Devices (India), Devon Innovations (India), ORMED Medical Technology (India) and Altron Industries (India).

It clients includes names like Manipal Groups of hospitals, Escorts Heart Hospital, Wockhardt Heart Hospitals, Apollo Group of Hospitals, Lilavati hospital, Breach Candy Hospital are among others.

In January 2009, the company’s California-based Mediaid Inc., the subsidiary company and the international marketing arm of the company had received Brazilian FDA agency - Agencia Nacional de Vigilancia Sanitaria (ANVISA) - approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the country and surrounding geographies.

During December, 2010 Opto Circuits (India) has successfully acquired 76% of outstanding common stock of Cardiac Science Corporation US. The company plans to exercise its top-up option under the terms of the merger agreement. The merger is expected to occur in the next few days. Following the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits (India).

Products

Health Care products- Under this segment it manufactures Pulse Oximeters, Pulse Oximeter Sensors, Fluid warmers, Digital Thermometer,Cholesterol Monitors And Stent.

Opto Electronics products- The Company manufactures Infrared Emitters, Infra Red Detectors, Photo Sensor, Detector and Emitter Assemblies.

Recognition

The company has ISO 9001-2000 and ISO 13485-2003 quality system certification.

OCI has received 2 Star Trading House Status in accordance with the provisions of Exim Policy of Federal Government of India.

Opto Circuits (India) has been featured in Forbes Asia’s 200 ‘Best Under a Billion’ List, 2011 by Forbes magazine. This is the third time the company has made it to this list, the last two times being 2008 and 2009.

Milestones

2010
- Opto Circuits acquisition of Unetixs Vascular creates strong synergies for Criticare Systems.
- Opto Circuits Successfully Completes Acquisition of Cardiac Science.
- Opto Circuits forays into manufacturing of cardiac stents - acquires Kolkata based N.S. Remedies.

2011
- Opto Circuits presents Bangalore Metro Rail Corporation Ltd. it's first public access defibrillator.
- Opto Circuits launches campaign to promote heart safe environments on World Heart Day.
- Opto Circuits ranked amongst Forbes' Asia's 200 Best Under a Billion companies for third year.

2012
- Opto Circuits launches new Powerheart G5 AED.
- Opto Circuits Supplies AEDs to 2012 UEFA European Football Championship.
- Opto Circuits launches its first Sirolimus Drug Eluting Stent."

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.23%
1 Week
-2.86%
1 Month
-15.33%
3 Month
-7.53%
6 Month
-16.13%
1 Year
-51.16%
2 Year
+23.12%
5 Year
-67.57%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 37.41 20.23 4.18 -7.52 -2.03 -42.35 4.70 5.68 -344.88
Return on Capital Employed (%) 22.40 15.45 6.79 -0.31 0.24 -21.91 2.52 3.26 -103.79
Return on Assets (%) 17.72 9.88 2.10 -3.71 -1.00 -18.83 1.70 2.49 -85.11

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 1,699 2,082 2,229 1,952 1,688 854 943 1,160 -76
Non Curr. Liab. 242 165 124 -52 199 110 76 101 173
Curr. Liab. 1,514 2,002 1,921 2,261 1,307 1,209 979 870 1,012
Minority Int. 18 21 20 19 18 13 12 12 -10
Equity & Liab. 3,473 4,269 4,293 4,181 3,212 2,186 2,009 2,143 1,099
Non Curr. Assets 1,455 1,268 1,226 1,052 2,041 1,651 1,748 1,856 932
Curr. Assets 2,017 3,000 3,066 3,128 1,171 534 261 287 167
Misc. Exp. not W/O 0 1 1 1
Total Assets 3,473 4,269 4,293 4,181 3,212 2,186 2,009 2,143 1,099

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 2,357 2,399 1,408 1,187 313 215 228 258 181
Other Income 14 7 63 25 34 1 1 2 5
Total Income 2,370 2,407 1,471 1,212 347 216 230 260 186
Total Expenditure -1,740 -1,805 -1,144 -948 -306 -192 -176 -192 -157
PBIDT 630 602 327 264 41 24 53 68 29
Interest -59 -109 -137 -144 -44 -17 -6 -3 -29
Depreciation -55 -96 -76 -95 -41 -16 -13 -11 -6
Taxation 57 -3 -22 -2 -1 -1 -1 -2 0
Exceptional Items -11 -2 -181 9 -499 2 -1,374
PAT 573 382 90 -157 -37 -508 36 52 -1,380

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 127 -140 0 -145 724 309 70 45 72
Cash Fr. Inv. -337 -102 -11 83 -9 -118 4 17 -150
Cash Fr. Finan. 151 111 -12 68 -732 -191 -71 -69 76
Net Change -60 -131 -23 6 -16 -1 3 -7 -1
Cash & Cash Eqvt 174 43 20 26 10 8 11 4 3

Shareholding Pattern View Details

9 Qtrs 2018-12 (%) 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%)
Promoter 20.95 19.30 19.48 19.48 19.48 19.48 19.48 18.52 18.52
Public 79.05 80.70 80.52 80.52 80.52 80.52 80.52 81.48 81.48
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 08 Jul 2021
Closure of Trading Window
Closure of Trading Window
Wed, 26 May 2021
Eurocor Tech Gmbh Launches Innovative New Sirolimus Coated Stent Eurolimus™
Eurocor Tech GmbH launches innovative new Sirolimus Coated Stent Eurolimus™
Wed, 21 Apr 2021
Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0110
Name of the Signatory :- SOMADAS G C
Designation :- Managing Director / Whole Time Director

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Both SRS And ARS Below Zero Both SRS And ARS Below Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%